Suppr超能文献

宏基因组下一代测序检测通用病原体的验证

Validation of Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection.

作者信息

Schlaberg Robert, Chiu Charles Y, Miller Steve, Procop Gary W, Weinstock George

机构信息

From the Department of Pathology, University of Utah, and the Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah (Dr Schlaberg); the Departments of Laboratory Medicine and Medicine, University of California, San Francisco (Dr Chiu); the Departments of Pathology and Laboratory Medicine, University of California, San Francisco (Dr Miller); the Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio (Dr Procop); and The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut (Dr Weinstock).

出版信息

Arch Pathol Lab Med. 2017 Jun;141(6):776-786. doi: 10.5858/arpa.2016-0539-RA. Epub 2017 Feb 7.

Abstract

CONTEXT

  • Metagenomic sequencing can be used for detection of any pathogens using unbiased, shotgun next-generation sequencing (NGS), without the need for sequence-specific amplification. Proof-of-concept has been demonstrated in infectious disease outbreaks of unknown causes and in patients with suspected infections but negative results for conventional tests. Metagenomic NGS tests hold great promise to improve infectious disease diagnostics, especially in immunocompromised and critically ill patients.

OBJECTIVE

  • To discuss challenges and provide example solutions for validating metagenomic pathogen detection tests in clinical laboratories. A summary of current regulatory requirements, largely based on prior guidance for NGS testing in constitutional genetics and oncology, is provided.

DATA SOURCES

  • Examples from 2 separate validation studies are provided for steps from assay design, and validation of wet bench and bioinformatics protocols, to quality control and assurance.

CONCLUSIONS

  • Although laboratory and data analysis workflows are still complex, metagenomic NGS tests for infectious diseases are increasingly being validated in clinical laboratories. Many parallels exist to NGS tests in other fields. Nevertheless, specimen preparation, rapidly evolving data analysis algorithms, and incomplete reference sequence databases are idiosyncratic to the field of microbiology and often overlooked.
摘要

背景

宏基因组测序可通过无偏差的鸟枪法新一代测序(NGS)用于检测任何病原体,无需进行序列特异性扩增。在不明原因的传染病暴发以及疑似感染但传统检测结果为阴性的患者中,已证实了其概念验证。宏基因组NGS检测在改善传染病诊断方面具有巨大潜力,尤其是在免疫功能低下和重症患者中。

目的

讨论在临床实验室中验证宏基因组病原体检测试验的挑战并提供示例解决方案。提供了当前监管要求的总结,主要基于先前在体质遗传学和肿瘤学中进行NGS检测的指南。

数据来源

提供了来自2项独立验证研究的示例,涵盖从分析设计、湿实验台和生物信息学方案的验证到质量控制和保证的各个步骤。

结论

尽管实验室和数据分析工作流程仍然复杂,但用于传染病的宏基因组NGS检测在临床实验室中越来越多地得到验证。与其他领域的NGS检测存在许多相似之处。然而,样本制备、快速发展的数据分析算法以及不完整的参考序列数据库是微生物学领域所特有的,并且常常被忽视。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验